Equities Analysts Issue Forecasts for Geron FY2026 Earnings

Geron Co. (NASDAQ:GERN) – Stock analysts at Wedbush decreased their FY2026 earnings estimates for Geron in a report released on Wednesday, February 26th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will earn $0.07 per share for the year, down from their prior estimate of $0.11. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

GERN has been the subject of several other reports. B. Riley cut Geron from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $3.50 to $2.00 in a research report on Thursday. Barclays reaffirmed an “overweight” rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC reduced their target price on shares of Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. Stifel Nicolaus lowered their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Scotiabank cut their price objective on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Price Performance

NASDAQ:GERN opened at $1.76 on Friday. The firm has a market cap of $1.06 billion, a P/E ratio of -5.50 and a beta of 0.53. The stock has a 50 day moving average of $2.97 and a two-hundred day moving average of $3.80. Geron has a 12 month low of $1.46 and a 12 month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million.

Institutional Trading of Geron

Hedge funds have recently made changes to their positions in the company. RTW Investments LP acquired a new position in Geron in the third quarter valued at approximately $200,268,000. Holocene Advisors LP acquired a new position in shares of Geron in the 3rd quarter valued at $82,498,000. Janus Henderson Group PLC lifted its stake in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after purchasing an additional 13,163,889 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Geron by 947.6% during the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 9,950,000 shares during the period. Finally, Braidwell LP acquired a new stake in shares of Geron during the 4th quarter worth about $24,802,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.